SG10201408415PA - HUMANIZED FCγ R MICE - Google Patents

HUMANIZED FCγ R MICE

Info

Publication number
SG10201408415PA
SG10201408415PA SG10201408415PA SG10201408415PA SG10201408415PA SG 10201408415P A SG10201408415P A SG 10201408415PA SG 10201408415P A SG10201408415P A SG 10201408415PA SG 10201408415P A SG10201408415P A SG 10201408415PA SG 10201408415P A SG10201408415P A SG 10201408415PA
Authority
SG
Singapore
Prior art keywords
mice
humanized
genetically modified
fcγ
locus
Prior art date
Application number
SG10201408415PA
Inventor
Lynn Macdonald
Naxin Tu
Cagan Gurer
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201408415P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201408415PA publication Critical patent/SG10201408415PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)

Abstract

HUMANIZED F R MICE C γ Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc R locus, and wherein the mouse is capable of expressing a γ functional FcR -chain. Genetically modified mice are described, including mice that express γ low affinity human Fc R genes from the endogenous Fc R locus, and wherein the mice γ γ comprise a functional FcR -chain. Genetically modified mice that express up to five low γ affinity human Fc R genes on accessory cells of the host immune system are provided. γ [Fig.6]
SG10201408415PA 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE SG10201408415PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
SG10201408415PA true SG10201408415PA (en) 2015-01-29

Family

ID=43601078

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202011814TA SG10202011814TA (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE
SG2012043683A SG181690A1 (en) 2009-12-21 2010-12-17 Humanized fcy r mice
SG10201408415PA SG10201408415PA (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10202011814TA SG10202011814TA (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE
SG2012043683A SG181690A1 (en) 2009-12-21 2010-12-17 Humanized fcy r mice

Country Status (25)

Country Link
US (8) US8658154B2 (en)
EP (3) EP3498730A1 (en)
JP (4) JP5595517B2 (en)
KR (4) KR102092744B1 (en)
CN (2) CN102762590B (en)
AU (3) AU2010339863B2 (en)
CA (2) CA2784953C (en)
CY (1) CY1120316T1 (en)
DK (1) DK2516457T3 (en)
ES (1) ES2671188T3 (en)
HK (1) HK1257001A1 (en)
HR (1) HRP20180911T1 (en)
HU (1) HUE038684T2 (en)
IL (4) IL220365A (en)
LT (1) LT2516457T (en)
MY (1) MY156743A (en)
NO (1) NO2516457T3 (en)
PL (1) PL2516457T3 (en)
PT (1) PT2516457T (en)
RS (1) RS57280B1 (en)
RU (1) RU2549695C2 (en)
SG (3) SG10202011814TA (en)
SI (1) SI2516457T1 (en)
TR (1) TR201808011T4 (en)
WO (1) WO2011084664A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
MY172726A (en) * 2011-10-28 2019-12-11 Regeneron Pharma Humanized il-6 and il-6 receptor
RU2014120375A (en) * 2011-11-01 2015-12-10 Рош Гликарт Аг ANTIBODY-DEPENDENT CELL CYTOTOXICITY MODEL IN A LIVING ORGANISM
WO2014071397A2 (en) * 2012-11-05 2014-05-08 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
DE202014010413U1 (en) 2013-09-18 2015-12-08 Kymab Limited Cells and organisms
PL2908626T3 (en) * 2013-10-15 2017-05-31 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
RU2685914C1 (en) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification
CA2942697A1 (en) * 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
PL3129400T3 (en) 2014-04-08 2020-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals having humanized fc-gamma receptors
KR102457921B1 (en) * 2014-12-09 2022-10-25 리제너론 파마슈티칼스 인코포레이티드 Non-human animals having a humanized cluster of differentiation 274 gene
PT3282835T (en) * 2015-04-13 2023-07-25 Univ Yale Humanized sirpa-il15 knockin mice and methods of use thereof
WO2016175285A1 (en) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 TRANSGENIC NON-HUMAN ANIMAL EXPRESSING HUMAN-SPECIFIC MOLECULES AND HUMAN FCγ RECEPTOR FAMILY
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
EP3861854A4 (en) * 2018-09-27 2022-01-26 Central Institute For Experimental Animals Immunodeficient mouse
JP6935383B2 (en) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 Immunodeficient mouse
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20230147048A (en) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 Mice expressing humanized Fc alpha receptors
JP7131650B1 (en) 2021-04-28 2022-09-06 井関農機株式会社 Threshing device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0149012B1 (en) 1988-05-27 1998-08-17 쇼트보르그 레기날드 데 Human fc-gamma receptor ñ
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
JP2003531149A (en) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ Enhancement of antibody-derived immune response
RU2262511C2 (en) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Humanized monoclonal antibody raised against ailim, co-stimulating molecule for signal transfer and its pharmaceutical applying
AU2002222951A1 (en) 2000-07-18 2002-01-30 Geoff D. Koch Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (en) 2001-03-15 2003-09-19 Genoway TRANSGENIC CELL AND ANIMAL MODELING IGE MEDIATED ALLERGIC RESPONSES AND USES THEREOF
JP4653915B2 (en) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 Systemic lupus erythematosus model non-human animal
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003104459A1 (en) 2002-06-07 2003-12-18 Arthron Limited Fcyriia transgenic animal model for autoimmune disease
JP2004147535A (en) 2002-10-29 2004-05-27 Japan Science & Technology Agency Guillain-barre syndrome and / or fisher syndrome-developing model non-human animal
KR20050084317A (en) * 2002-12-16 2005-08-26 제넨테크, 인크. Transgenic mice expressing human cd20 and/or cd16
FR2858235B1 (en) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS
KR101149242B1 (en) * 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Fc region variants
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
JP2009529331A (en) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド Identification and engineering modification of antibodies having mutated heavy chains and methods of use thereof
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
MX2009002414A (en) * 2006-09-08 2009-05-20 Medimmune Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease.
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
PL2178916T3 (en) 2007-07-31 2015-08-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
US20110119779A1 (en) * 2007-12-10 2011-05-19 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
ES2665068T3 (en) 2008-03-07 2018-04-24 Regeneron Pharmaceuticals, Inc. Mice derived from ES cells from injection of a diploid host embryo
EP2318439A2 (en) * 2008-07-23 2011-05-11 Rappaport Family Institute for Research in the Medical Sciences Methods of altering peripheral b cell populations and uses thereof
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
US20140157445A1 (en) 2014-06-05
US8658154B2 (en) 2014-02-25
TR201808011T4 (en) 2018-06-21
PL2516457T3 (en) 2018-08-31
ES2671188T3 (en) 2018-06-05
IL242719A (en) 2017-09-28
SI2516457T1 (en) 2018-08-31
KR20190045404A (en) 2019-05-02
HRP20180911T1 (en) 2018-07-13
IL261257B (en) 2019-12-31
JP2013514778A (en) 2013-05-02
KR102092744B1 (en) 2020-03-24
SG181690A1 (en) 2012-07-30
AU2014210646A1 (en) 2014-08-28
CY1120316T1 (en) 2019-07-10
JP2014132909A (en) 2014-07-24
KR20200033981A (en) 2020-03-30
US20200061213A1 (en) 2020-02-27
CN104232589B (en) 2018-04-27
AU2010339863A1 (en) 2012-07-12
JP6073840B2 (en) 2017-02-01
US9687566B2 (en) 2017-06-27
EP2516457A1 (en) 2012-10-31
CN104232589A (en) 2014-12-24
US9056130B2 (en) 2015-06-16
IL220365A0 (en) 2012-08-30
AU2010339863B2 (en) 2014-07-17
IL271083A (en) 2020-01-30
EP2516457B9 (en) 2021-09-29
EP3336102A2 (en) 2018-06-20
EP3498730A1 (en) 2019-06-19
CA2784953A1 (en) 2011-07-14
PT2516457T (en) 2018-06-12
SG10202011814TA (en) 2021-01-28
IL220365A (en) 2016-11-30
AU2014210645A1 (en) 2014-08-28
DK2516457T3 (en) 2018-06-18
MY156743A (en) 2016-03-31
AU2014210646B2 (en) 2016-06-23
RS57280B1 (en) 2018-08-31
CA3000246C (en) 2021-05-25
NO2516457T3 (en) 2018-08-11
HK1257001A1 (en) 2019-10-11
KR20180058860A (en) 2018-06-01
US20210346522A1 (en) 2021-11-11
CA3000246A1 (en) 2011-07-14
CA2784953C (en) 2018-05-22
US20110154512A1 (en) 2011-06-23
US20150313195A1 (en) 2015-11-05
US11020495B2 (en) 2021-06-01
RU2012131296A (en) 2014-01-27
AU2014210645B2 (en) 2016-05-19
US9089599B2 (en) 2015-07-28
JP5595517B2 (en) 2014-09-24
WO2011084664A1 (en) 2011-07-14
US10426848B2 (en) 2019-10-01
JP5891259B2 (en) 2016-03-22
CN102762590A (en) 2012-10-31
HUE038684T2 (en) 2018-11-28
KR101862277B1 (en) 2018-06-01
US8658853B2 (en) 2014-02-25
JP2016093201A (en) 2016-05-26
US20180015185A1 (en) 2018-01-18
LT2516457T (en) 2018-06-11
IL261257A (en) 2018-10-31
KR102178064B1 (en) 2020-11-12
CN102762590B (en) 2015-11-25
JP2014209923A (en) 2014-11-13
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
US20120260357A1 (en) 2012-10-11
KR101973524B1 (en) 2019-09-02
RU2549695C2 (en) 2015-04-27
KR20120102138A (en) 2012-09-17
US20140154701A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
SG10201408415PA (en) HUMANIZED FCγ R MICE
EP4311833A3 (en) Genetically modified major histocompatibility complex mice
IL265570A (en) Genetically modified non-human animals and methods of use thereof
MX355726B (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules.
IN2013CN07629A (en)
MX2022002117A (en) Hybrid light chain mice.
WO2007117410A3 (en) Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MX368931B (en) Non-human animals having a humanized signal-regulatory protein gene.
MY172472A (en) Mice that make heavy chain antibodies
SG10201811116UA (en) Non-human animals having a humanized programmed cell death 1 gene
MX2019002482A (en) Genetically modified animals and methods for making the same.
FI3282835T3 (en) Humanized sirpa-il15 knockin mice and methods of use thereof
CA2853731C (en) Humanized il-6 and il-6 receptor
TR201903439T4 (en) Humanized light chain mice.
SG10201809157VA (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2008010100A3 (en) Immunodeficient mice transgenic for hla class i and hla class ii molecules and their uses
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
SG10201908800YA (en) Non-human animals having humanized fc-gamma receptors
SG10201803766UA (en) Lincrna-deficient non-human animals
MX2018009513A (en) Non-human animals having an engineered angptl8 gene.
MX2021000586A (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules.
WO2012148538A3 (en) Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
Assay 319. LMO2 Perturbs Human T Cell Development In Vivo by Two Different Mechanisms
NZ628189A (en) Therapeutic nuclease compositions and methods
WO2012005529A3 (en) Transgenic mice expressing human ferritin in a manner non-specific to tissue, and use thereof